• Edwards Lifesciences Corp EW.N, EW is expected to show a fall in quarterly revenue when it reports results on February 11 for the period ending December 31 2024

• The Irvine California-based company is expected to report a 11.5% decrease in revenue to $1.358 billion from $1.53 billion a year ago, according to the mean estimate from 24 analysts, based on LSEG data.The company's guidance on October 24 2024, for the period ended December 31, was for revenue between $1.33 billion and $1.39 billion.

• ​LSEG's mean analyst estimate for Edwards Lifesciences Corp is for earnings of 55 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 18 "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Edwards Lifesciences Corp is $78.07​, above​ its last closing price of $70.99. ​​​

The company's guidance on October 24 2024 for the period ended December 31 was for gross profit margin of USD78%.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated February 7 at 21:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)